Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck & Company (MRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 148,672,688
  • Shares Outstanding, K 2,724,440
  • Annual Sales, $ 40,122 M
  • Annual Income, $ 2,568 M
  • 36-Month Beta 0.75
  • Price/Sales 3.70
  • Price/Cash Flow 9.41
  • Price/Book 3.88

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.36 +2.76%
on 02/09/18
62.14 -11.76%
on 01/29/18
-6.87 (-11.13%)
since 01/23/18
3-Month
53.36 +2.76%
on 02/09/18
63.78 -14.02%
on 01/16/18
+0.47 (+0.86%)
since 11/22/17
52-Week
53.36 +2.76%
on 02/09/18
66.80 -17.91%
on 03/01/17
-11.01 (-16.73%)
since 02/23/17

Most Recent Stories

More News
Dow 30 Stock Roundup: Walmart Disappoints, Coca-Cola Impresses

The Dow experienced a volatile holiday shortened week, suffering losses during two trading sessions.

KO : 43.98 (+1.06%)
CVX : 112.47 (+2.35%)
MRK : 54.88 (+0.57%)
XOM : 77.46 (+2.11%)
TOT : 58.41 (+1.53%)
TRV : 139.23 (+1.16%)
GS : 266.24 (+1.84%)
WMT : 92.89 (+0.13%)
Pharma Stock Roundup: AZN's Imfinzi Gets 2nd FDA Nod, MRK to Buy Australian Firm

Key announcements this week included the FDA approval for a second indication of AstraZeneca's (AZN) Imfinzi and an acquisition offer by Merck (MRK).

AZN : 33.98 (+0.86%)
NVO : 53.79 (+1.38%)
VYGR : 28.48 (+10.13%)
MRK : 54.88 (+0.57%)
IONS : 50.76 (+1.76%)
ABBV : 118.51 (+0.81%)
ACOR : 26.00 (-1.52%)
BMY : 67.81 (+2.84%)
LYNPARZA(R) (olaparib) Receives Positive EU CHMP Opinion in Platinum-Sensitive Relapsed Ovarian Cancer

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

MRK : 54.88 (+0.57%)
Merck to Buy Australian Firm to Boost Immunotherapy Pipeline

Merck (MRK) to buy Australian oncolytic immunotherapies maker Viralytics Limited to strengthen its presence in the fast growing immuno-oncology market.

CELG : 95.41 (+1.74%)
MRK : 54.88 (+0.57%)
JUNO : 86.58 (+0.02%)
SNY : 40.21 (+0.90%)
OncoPep Announces Initiation of Phase 1b Clinical Trial of PVX-410 in Metastatic Triple Negative Breast Cancer

OncoPep, Inc. today announced the initiation of a Phase 1b clinical trial evaluating its investigational vaccine product PVX-410 for the treatment of patients with metastatic triple...

MRK : 54.88 (+0.57%)
Wired News - Gilead Sciences Rejoices as Federal Judge Reverses Judgement in $2.54 Billion Patent Infringement Case with Merck

LONDON, UK / ACCESSWIRE / February 21, 2018 / Active-Investors.com has just released a free research report on Gilead Sciences, Inc. (NASDAQ: GILD) ("Gilead"). If you want access to this report all you...

MRK : 54.88 (+0.57%)
GILD : 80.72 (+1.66%)
What's in Store for Agenus (AGEN) This Earnings Season?

Agenus (AGEN) is expected to provide updates on pipeline candidates when it reports Q4 numbers on Mar 8.

GEMP : 6.60 (-2.87%)
AGEN : 5.07 (+4.54%)
MRK : 54.88 (+0.57%)
EXEL : 29.34 (+0.82%)
Merck and Viralytics Announce Acquisition Agreement, Expanding Merck's Leading Immuno-Oncology Pipeline

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Viralytics Limited (ASX: VLA, OTC: VRACY) today announced that the companies have signed a definitive agreement under...

MRK : 54.88 (+0.57%)
VRACY : 4.1000 (+5.37%)
Merck Receives Two More Patents for CRISPR Technology

- Patents in South Korea and Israel cover integration of an external DNA sequence into the chromosome of eukaryotic cells

MRK : 54.88 (+0.57%)
AstraZeneca's (AZN) Imfinzi Gets FDA Nod for Label Expansion

Data shows that AstraZeneca's (AZN) Imfinzi improved PFS by more than 11 months in comparison to placebo in the concerned patient population.

AZN : 33.98 (+0.86%)
MRK : 54.88 (+0.57%)
NVS : 85.29 (+0.11%)
BMY : 67.81 (+2.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies...

See More

Key Turning Points

2nd Resistance Point 55.32
1st Resistance Point 54.95
Last Price 54.88
1st Support Level 54.31
2nd Support Level 54.04

See More

52-Week High 66.80
Fibonacci 61.8% 61.67
Fibonacci 50% 60.08
Fibonacci 38.2% 58.49
Last Price 54.88
52-Week Low 53.36

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.